Recommendations for acceleration of vaccine development and emergency use filings for COVID-19 leveraging lessons from the novel oral polio vaccine

A new oral polio vaccine, nOPV2, has become the first vaccine to pursue a WHO Emergency Use Listing. Many lessons were learned as part of the accelerated development plan and submission, which have been categorized under the following sections: regulatory, clinical development, chemistry manufacturi...

Descripción completa

Detalles Bibliográficos
Autores principales: Thiel, Natalie, Selwyn, Casey, Murphy, Georgina, Simpson, Shmona, Chakrabarti, Ajoy C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062661/
https://www.ncbi.nlm.nih.gov/pubmed/33888722
http://dx.doi.org/10.1038/s41541-021-00325-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062661/
https://www.ncbi.nlm.nih.gov/pubmed/33888722
http://dx.doi.org/10.1038/s41541-021-00325-4

Ejemplares similares